Comprehensive Biomarker Testing

Clarus Health's functional medicine programme analyses over 150 biomarkers spanning metabolic health, cardiovascular risk, hormonal balance, inflammatory status, nutritional sufficiency, microbiome, and mitochondrial function. Testing includes advanced lipid particles (apoB, Lp(a)), comprehensive thyroid panels, insulin resistance markers, adrenal function, inflammatory cytokines, and specialised panels for conditions such as ME/CFS, POTS, and PCOS. Results are interpreted by the Clarus physician team in the context of each client's symptoms, history, and goals — forming the foundation for a personalised treatment protocol rather than a reference-range checklist.

Clarus Health's biomarker testing programme goes substantially beyond a conventional annual blood panel, deploying a 150+ marker assessment designed to build a granular, functional picture of each patient's physiological status. The programme operates within the clinic's functional and concierge medicine framework, where test results are used not simply to identify disease-level abnormalities, but to detect sub-clinical imbalances and optimise function proactively. Cardiovascular risk assessment at Clarus extends beyond a standard lipid panel to include particle-level lipoprotein analysis: apolipoprotein B (apoB) — the most direct measure of atherogenic particle number — and lipoprotein(a), or Lp(a), an independent genetic cardiovascular risk factor not addressed by conventional LDL measurement. Inflammatory burden is quantified through high-sensitivity C-reactive protein (hs-CRP) and homocysteine, both established markers of systemic inflammation and endothelial injury risk. Thyroid function is assessed comprehensively — not limited to TSH alone, but including free T3, free T4, reverse T3, and thyroid antibodies (TPO and TGAb), providing a complete picture of thyroid axis function that may reveal subclinical hypothyroidism, Hashimoto's thyroiditis, or conversion impairment that a TSH-only test would miss. Adrenal function is characterised through cortisol rhythm and aldosterone panels; insulin resistance is quantified through fasting insulin and HOMA-IR rather than fasting glucose alone. For clients with complex presentations, Clarus offers condition-specific specialist panels. The ME/CFS evaluation protocol includes mitochondrial function markers, natural killer (NK) cell activity, inflammatory cytokine profiling, HPA axis assessment, and viral reactivation titres (EBV, HHV-6) — addressing the multi-system pathophysiology underlying chronic fatigue syndrome. POTS and dysautonomia workup includes catecholamines, plasma renin activity, and aldosterone. A PCOS/PMOS panel covers androgens, LH/FSH ratio, fasting insulin, HOMA-IR, SHBG, and AMH. Genomic testing via IntellxxDNA identifies variants in genes including COMT and MTHFR that affect neurotransmitter processing, methylation capacity, hormone metabolism, and nutrient requirements — enabling Clarus physicians to personalise protocols at the molecular level. Microbiome and GI health are also assessed through urine organic acids, stool analysis, and salivary testing. All testing is reviewed by the Clarus physician team in a comprehensive consultation, and results form the foundation of a longitudinal monitoring programme through the clinic's concierge primary care model.